Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.45 |
| ▸ | CTSD | P07339 | 3/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361652 | 0.96 | BACE1 (0.45) | BACE1CTSDFURINPDCD1LG2CD274 | |
| SCHEMBL32690572 | 0.92 | BACE1 (0.43) | BACE1CTSDFURIN | |
| SCHEMBL6117674 | 0.89 | FURIN (0.40) | BACE1CTSDFURIN | |
| SCHEMBL2467105 | 0.89 | FURIN (0.40) | BACE1CTSDFURIN | |
| SCHEMBL7922664 | 0.88 | CTSD (0.41) | BACE1CTSDFURIN | |
| SCHEMBL7922670 | 0.88 | CTSD (0.41) | BACE1CTSDFURIN | |
| SCHEMBL29404549 | 0.88 | ACE (0.46) | FURIN | |
| SCHEMBL32690573 | 0.87 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL32690445 | 0.87 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL29527624 | 0.87 | ACE (0.43) | FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | BACE1 4076/4885CTSD 1691/4885FURIN 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.